검색어: involved in the developments running up to (덴마크어 - 이탈리아어)

a. parties involved in the envisaged transaction
a. parties involved in the envisaged transaction

this report gives an analysis of the situation of the companies involved, the developments in the market and possible advantages for shetland seafish ltd to acquire whalsay ltd.
this report gives an analysis of the situation of the companies involved, the developments in the market and possible advantages for shetland seafish ltd to acquire whalsay ltd.

- the table below indicates the number of institutions by eu member state involved in the received and the funded applications.
- the table below indicates the number of institutions by eu member state involved in the received and the funded applications.

pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products
pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products

23 up to now , 12 member states participated and are participating in the project , providing data for several reference years ( up to 2001 ) .
23 up to now , 12 member states participated and are participating in the project , providing data for several reference years ( up to 2001 ) .

der findes allerede et omfangsrigt emnekatalog. et af de emner, der skal belyses, er: identification of thefactors involved in the increase in antimicrobial resistance.
esiste già una lunga se­rie di argomenti da esaminare, uno dei quali riguarda l'identificazione dei fattori implicati nell'aumento della resistenza antimicrobica.

concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus
investigation of medicinal products in the treatment of diabetes mellitus points to consider on clinical investigation

concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.
concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.

concept paper on the development of an addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure
concept paper on the development of an addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure

the specific aim expressed in the tender procedure will be to provide a subsidy towards the creation of new p&w paper reprocessing capacity and promote the development of recycled paper technology within this paper grade.
the specific aim expressed in the tender procedure will be to provide a subsidy towards the creation of new p&w paper reprocessing capacity and promote the development of recycled paper technology within this paper grade.

titel på dokumentet note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants revision of note for guidance on minimising the risks of tse transmission via medicinal products points to consider on the development of live attenuated influenza vaccines
titolo del documento note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants revision of note for guidance on minimising the risks of tse transmission via medicinal products points to consider on the development of live attenuated influenza vaccines

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

på engelsk duty fixed in the combined nomenclature reduced by 30,77 % up to the quantity indicated in boxes 17 and 18 of this licence (regulation (ec) no 327/98)
in inglese duty fixed in the combined nomenclature reduced by 30,77 % up to the quantity indicated in boxes 17 and 18 of this licence (regulation (ec) no 327/98)

med hensyn til eventuelle risici i forbindelse med udviklingen af bioteknologi erne bor nævnes den undersogelse, der er foretaget af sargeant og evans for ef-kommissionen (»hazards involved in the industrial use of micro-organisms«, dok.
(') a proposito degli eventuali rischi legati allo sviluppo della biotecnologia, va ricordato lo studio realizzato da sargeant e evans per la commissione (hazards involved in the industrial use of micro-organisms, doc.

(12) in addition, with regard to the aid granted under the fish factory improvement scheme the united kingdom states that during the years 1997 — 2005 aid has been granted under the scheme to a company involved in the production of fish meal and fish oil, not intended for human consumption, amounting to a total of gbp 93600.
(12) in addition, with regard to the aid granted under the fish factory improvement scheme the united kingdom states that during the years 1997 — 2005 aid has been granted under the scheme to a company involved in the production of fish meal and fish oil, not intended for human consumption, amounting to a total of gbp 93600.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: